Precigen (NASDAQ:PGEN) Stock Rating Upgraded by Wall Street Zen

Precigen (NASDAQ:PGEN - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a report issued on Saturday.

Other research analysts have also issued research reports about the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Precigen in a research note on Thursday, May 15th. HC Wainwright reaffirmed a "buy" rating and set a $6.00 price target on shares of Precigen in a research note on Thursday, March 20th. Finally, JMP Securities reissued a "market outperform" rating and set a $6.00 price target on shares of Precigen in a research report on Thursday, June 12th.

Precigen Stock Performance

NASDAQ:PGEN traded down $0.10 during trading hours on Friday, hitting $1.86. The company's stock had a trading volume of 1,059,825 shares, compared to its average volume of 1,469,134. The company has a market capitalization of $547.56 million, a PE ratio of -3.31 and a beta of 1.78. The business's 50-day moving average is $1.46 and its two-hundred day moving average is $1.49. Precigen has a 52-week low of $0.65 and a 52-week high of $2.17.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its earnings results on Wednesday, May 14th. The biotechnology company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. The business had revenue of $1.34 million during the quarter, compared to the consensus estimate of $0.50 million. Precigen had a negative return on equity of 279.20% and a negative net margin of 3,728.87%. As a group, analysts predict that Precigen will post -0.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Precigen

Several large investors have recently bought and sold shares of the stock. Voya Investment Management LLC lifted its position in shares of Precigen by 142.9% during the 1st quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 21,633 shares during the last quarter. Inspire Investing LLC bought a new position in shares of Precigen during the 1st quarter valued at approximately $350,000. Strs Ohio purchased a new stake in shares of Precigen during the 1st quarter valued at $70,000. Parkman Healthcare Partners LLC purchased a new position in shares of Precigen during the first quarter valued at about $4,755,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Precigen by 12.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 81,610 shares of the biotechnology company's stock worth $122,000 after acquiring an additional 9,043 shares during the period. Hedge funds and other institutional investors own 33.51% of the company's stock.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.